Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Centro Hospitalar De Trás-Os-Montes E Alto Douro, E.P.E.

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

Centro Hospitalar de Trás-os-Montes e Alto Douro, E.P.E. (CHTMAD), which now integrates into the broader Unidade Local de Saúde de Trás-os-Montes e Alto Douro (ULSTMAD), is the largest hospital center in Portugal in terms of geographic coverage. Headquartered in Vila Real, Portugal with a facility at R. dos Lagoeiros 43, this public healthcare network services a regional population of approximately 300,000 to 410,000 inhabitants across 22 municipalities. The institution combines the clinical operations of three primary hospital units—located in Vila Real, Chaves, and Lamego—alongside a specialized Palliative Care unit in Vila Pouca de Aguiar.

Business Status

Source: Google. OPEN

Business Category

Source: Google. Hospital

Business Subcategory

Source: Google. Hospital
Source: Trial-derived.
9Total Trials
Source: Trial-derived.
1Recruiting Trials
Source: Trial-derived.
5Active Trials
Source: Trial-derived.
4Completed Trials
Source: Trial-derived.
19Unique Conditions
Source: Trial-derived.
11Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (2)Source: Trial-derived. Atherosclerosis of Femoral Artery (1)Source: Trial-derived. Carcinoma, Hepatocellular (1)Source: Trial-derived. Chemotherapy-induced Thrombocytopenia (1)Source: Trial-derived. Chronic Limb Ischemia (1)Source: Trial-derived. Chronic Limb-Threatening Ischemia (1)Source: Trial-derived. Colostomy Stoma (1)Source: Trial-derived. Early Breast Cancer (1)

Sponsors

Source: Trial-derived. Amgen (1)Source: Trial-derived. AstraZeneca (1)Source: Trial-derived. Daiichi Sankyo (1)Source: Trial-derived. Daiichi Sankyo Co., Ltd. (1)Source: Trial-derived. Eisai Inc. (1)Source: Trial-derived. Hoffmann-La Roche (1)Source: Trial-derived. Hospital do Divino Espírito Santo de Ponta Delgada (1)Source: Trial-derived. Hydrumedical (1)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. PCR / molecular

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling
Source: AI-inferred. Sterile preparation (laminar-flow hood / BSC or cleanroom)

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Radiation therapy
Source: AI-inferred. Tumour tissue biopsy (guidance not stated)

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Cystoscopy
Source: AI-inferred. Transurethral intravesical device placement via urinary catheter
Source: AI-inferred. Transurethral resection of bladder tumour (TURBT)